Enclomiphene

Overview

Enclomiphene is the (E)/trans-isomer of clomifene and a selective estrogen receptor modulator (SERM) — a small molecule of the triphenylethylene class, not a peptide. It is the isomer that carries clomifene's anti-estrogenic activity. By blocking estrogen's negative feedback at the hypothalamus and pituitary, it increases GnRH pulsatility and raises pituitary LH and FSH, which in turn stimulate the testes to produce more of a man's own testosterone — while preserving spermatogenesis and the HPG axis. That is the key contrast with exogenous testosterone (gels or injections), which suppress LH/FSH and reduce sperm counts; reviewers frame enclomiphene as "restoration" rather than "replacement."

Its clinical development is a cautionary detail: as Androxal (Repros Therapeutics) it reached phase 3 for male secondary hypogonadism, but the application was not approved by the FDA and development was discontinued — so, despite the promising trial data, there is no approved enclomiphene product anywhere. It reaches people through compounding pharmacies and grey-market "research chemical" vendors, and this page describes what the trials showed while giving no dosing, protocol, or "restart" schedule.

Chemistry and structure

Enclomiphene and zuclomiphene are stereoisomers (same formula C26H28ClNO); identity is best anchored to the (E)/(Z) designation, the PubChem CID and the InChIKey rather than to older, sometimes-reversed "cis/trans" labels. Enclomiphene is the (E) isomer, commonly called "trans-clomifene."

Mechanism of action

• Estrogen-receptor antagonism at the hypothalamus/pituitary. Enclomiphene blocks estrogen negative feedback centrally, which raises GnRH pulsatility and pituitary LH/FSH. [Human]
• Endogenous testosterone, fertility preserved. The rise in LH stimulates testicular Leydig cells to make more of the body's own testosterone, while FSH support keeps sperm production intact — "restoration," not "replacement." [Human]
• Contrast with testosterone therapy. Exogenous testosterone suppresses LH/FSH and impairs spermatogenesis; enclomiphene works the opposite way, which is the basis of its interest for men who want to raise testosterone without losing fertility. [Human]
• Isomer note. The co-isomer zuclomiphene is more estrogenic and very long-lived (~30 days), which is why the single (E)-isomer was pursued.

Research and evidence

The evidence base is a set of small, industry-sponsored trials in men with secondary hypogonadism, consistently showing enclomiphene raises testosterone into the normal range while preserving or increasing LH, FSH and sperm counts — unlike topical testosterone.

Human evidence. Reproducible and mechanism-consistent, but the program did not meet the FDA bar for approval: the endpoints were biochemical (testosterone, LH/FSH, sperm), not hard clinical outcomes, and long-term efficacy/safety data are lacking. The FDA raised concerns about trial design, entry criteria and the clinical meaningfulness of a testosterone rise without a clear symptom benefit, and the program was discontinued (a 2016 review summarises the evidence: Rodriguez et al., Expert Opin Pharmacother 2016). Treat enclomiphene as investigational and unapproved, not a proven therapy.

Status and regulation

There is no approved enclomiphene monoproduct (US or EU). The Androxal phase 3 program was not approved and was discontinued. Clomifene citrate (the mixture) is FDA-approved only for female ovulation induction/infertility — male use is off-label. Enclomiphene reaches patients via compounding (legal with a valid prescription, as a component of approved clomifene) and via grey-market "research chemical" vendors; it is illegal to sell as a dietary-supplement ingredient.

WADA status: prohibited at all times as a SERM under S4 (Hormone and Metabolic Modulators; clomifene is explicitly named, and enclomiphene falls under the same class). Sport eligibility is a separate axis from legality.

Safety

• Visual disturbances (blurred vision, light flashes, scintillating scotomata) — a recognised SERM/clomifene class effect.
• Mood changes / depression — reported as a class effect.
• Venous thromboembolism — a labeled class-level risk for clomifene/SERMs (not specifically quantified for enclomiphene).
• Most common in enclomiphene trials: elevated estradiol, headache, and nausea/abdominal discomfort — generally mild.
• Long-term safety unknown — never approved; no long-term controlled outcome data; effects on bone and cardiovascular risk incompletely characterised.
• Grey-market material carries no guarantee of identity, purity, sterility or potency, and none of the supervised-trial safety framing applies.

Legal status

Enclomiphene's status is best described by its regulatory classification: an unapproved investigational drug. "No specific ban" is not affirmative permission, and a compound becomes an unauthorised medicine the moment it is intended for human use. It is illegal to sell as a dietary supplement; grey-market "research chemical" material is unregulated. Clomifene's female approval does not confer legality on enclomiphene for men. WADA prohibition (S4) is separate from legality. This is not legal or medical advice; status and enforcement differ by country and change over time — verify your own jurisdiction. (Dated 2026-07-19.)

How it compares

• Gonadorelin — synthetic GnRH acting on the pituitary; a different molecular class (a peptide) and mechanism, though also aimed at driving LH/FSH.
• hCG — an LH mimetic acting directly on the gonad; enclomiphene instead works centrally, freeing the man's own pituitary LH/FSH. Both are used off-label to raise testosterone while preserving fertility, but at different levels of the axis.
• Clomifene (Clomid) — the isomeric mixture enclomiphene is derived from, approved for female infertility only; enclomiphene is the single anti-estrogenic isomer, without the long-lived zuclomiphene component.

Common misconceptions

• "Enclomiphene is a peptide." No — it is a small-molecule SERM (triphenylethylene class).
• "Enclomiphene is an approved men's testosterone drug." No — the Androxal phase 3 program was not approved and was discontinued; there is no approved enclomiphene product.
• "It's basically the same as Clomid." Clomid (clomifene) is the isomeric mixture and is approved only for women; enclomiphene is the single (E)-isomer, without the long-lived, more-estrogenic zuclomiphene.
• "The trials prove it works." They show a reproducible biochemical effect (testosterone up, sperm preserved), but on surrogate endpoints, and they did not earn FDA approval; it is investigational.
• "Legal to buy as a research chemical or supplement." It is illegal to sell as a supplement, it is WADA-prohibited, and grey-market material is unregulated — not a lawful medicine for human use.